search
Back to results

Evaluation of Amniotic Fluid Product in Knee Osteoarthritis

Primary Purpose

Osteoarthritis of the Knee

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Amniotic Fluid 4.0ml dose
Amniotic Fluid 2.0ml dose
Placebo Control
Sponsored by
MiMedx Group, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis of the Knee focused on measuring OA, Osteoarthritis, Knee

Eligibility Criteria

30 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject is 30 years or older.
  2. Subject has a diagnosis of osteoarthritis (OA) defined as Grade 1 to 3 on the Kellgren Lawrence grading scale.
  3. Subject is willing and able provide informed consent and participate in all procedures and follow-up evaluations necessary to complete the study.

Exclusion Criteria:

  1. Subject has active infection at the injection site.
  2. Subject has rheumatoid arthritis, psoriatic arthritis, or have been diagnosed with any other auto-immune disorders that could be the cause of their knee pain.
  3. BMI greater than 45 kg/m2
  4. Subject has received an intra-articular hyaluronic acid (HA) injection for the treatment of OA of the target knee within 3 months prior to screening.
  5. Subject has received a steroid or platelet rich plasma (PRP) injection for the treatment of OA of the target knee within 3 months prior to screening.
  6. Subject has had major surgery, arthroplasty or arthroscopy in the target knee within 26 weeks of treatment or plans to have surgery in the target knee within 180 days of treatment.
  7. Subject is pregnant or plans to become pregnant within 180 days of treatment.
  8. Subject has used an investigational drug, device or biologic within 12 weeks prior to treatment.
  9. Subject has any significant medical condition that, in the opinion of the Investigator, would interfere with protocol evaluation and participation.
  10. Subject has a history of immunosuppressive or chemotherapy in the last 5 years
  11. Subject has autoimmune disease or a known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV
  12. Subject has had prior radiation at the site
  13. Subject is currently taking anticoagulant therapy (excluding Plavix or Aspirin)
  14. Diagnosis of gout in the past 6 month
  15. Subject has a diagnosis of osteoarthritis

Sites / Locations

  • Central Research Associates, Inc
  • Weil Foot, Ankle and Orthopedic Institute

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

AF 4.0

AF 2.0

Placebo

Arm Description

Amniotic Fluid 4.0ml dose

Amniotic Fluid 2.0ml dose

Saline Placebo Control

Outcomes

Primary Outcome Measures

Reduction in Pain

Secondary Outcome Measures

Range of Motion
Knee injury and Osteoarthritis Outcome Score (KOOS)
WOMAC
Kellgren-Lawrence grade of OA

Full Information

First Posted
May 6, 2016
Last Updated
October 25, 2017
Sponsor
MiMedx Group, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02768155
Brief Title
Evaluation of Amniotic Fluid Product in Knee Osteoarthritis
Official Title
Protocol for the Clinical Evaluation Amniotic Fluid (AF) Product in Knee Osteoarthritis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
April 2016 (undefined)
Primary Completion Date
April 2017 (Actual)
Study Completion Date
July 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
MiMedx Group, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A study evaluating Amniotic Fluid compared to a Saline Placebo Injection in the treatment of subjects with osteoarthritic (OA) knee pain

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis of the Knee
Keywords
OA, Osteoarthritis, Knee

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
AF 4.0
Arm Type
Experimental
Arm Description
Amniotic Fluid 4.0ml dose
Arm Title
AF 2.0
Arm Type
Experimental
Arm Description
Amniotic Fluid 2.0ml dose
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Saline Placebo Control
Intervention Type
Other
Intervention Name(s)
Amniotic Fluid 4.0ml dose
Intervention Description
Injection of Amniotic Fluid
Intervention Type
Other
Intervention Name(s)
Amniotic Fluid 2.0ml dose
Intervention Description
Injection of Amniotic Fluid
Intervention Type
Other
Intervention Name(s)
Placebo Control
Intervention Description
Normal Saline
Primary Outcome Measure Information:
Title
Reduction in Pain
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Range of Motion
Time Frame
3 month
Title
Knee injury and Osteoarthritis Outcome Score (KOOS)
Time Frame
3 month
Title
WOMAC
Time Frame
3 month
Title
Kellgren-Lawrence grade of OA
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject is 30 years or older. Subject has a diagnosis of osteoarthritis (OA) defined as Grade 1 to 3 on the Kellgren Lawrence grading scale. Subject is willing and able provide informed consent and participate in all procedures and follow-up evaluations necessary to complete the study. Exclusion Criteria: Subject has active infection at the injection site. Subject has rheumatoid arthritis, psoriatic arthritis, or have been diagnosed with any other auto-immune disorders that could be the cause of their knee pain. BMI greater than 45 kg/m2 Subject has received an intra-articular hyaluronic acid (HA) injection for the treatment of OA of the target knee within 3 months prior to screening. Subject has received a steroid or platelet rich plasma (PRP) injection for the treatment of OA of the target knee within 3 months prior to screening. Subject has had major surgery, arthroplasty or arthroscopy in the target knee within 26 weeks of treatment or plans to have surgery in the target knee within 180 days of treatment. Subject is pregnant or plans to become pregnant within 180 days of treatment. Subject has used an investigational drug, device or biologic within 12 weeks prior to treatment. Subject has any significant medical condition that, in the opinion of the Investigator, would interfere with protocol evaluation and participation. Subject has a history of immunosuppressive or chemotherapy in the last 5 years Subject has autoimmune disease or a known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV Subject has had prior radiation at the site Subject is currently taking anticoagulant therapy (excluding Plavix or Aspirin) Diagnosis of gout in the past 6 month Subject has a diagnosis of osteoarthritis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Donald Fetterolf, MD
Organizational Affiliation
MiMedx Group, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Central Research Associates, Inc
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35205
Country
United States
Facility Name
Weil Foot, Ankle and Orthopedic Institute
City
Des Plaines
State/Province
Illinois
ZIP/Postal Code
60016
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of Amniotic Fluid Product in Knee Osteoarthritis

We'll reach out to this number within 24 hrs